Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial

European Journal of Heart Failure

Volumn 21, Issue 10, 2019, Pages 1270-1278

  Packer, Milton ^a,b,l   Butler, Javed ^c,l   Filippatos, Gerasimos ^l   Jamal, Waheed ^f   Salsali, Afshin ^g   Schnee, Janet ^g   Kimura, Karen ^h   Zeller, Cordula ^f   George, Jyothis ^f,l   Brueckmann, Martina ^f,i,l   Anker, Stefan D ^j,l   Zannad, Faiez ^k,l   Perrone, Sergio ^l   Nicholls, Stephen ^l   Janssens, Stefan ^l   Bocchi, Edmar ^l   Giannetti, Nadia ^l   Verma, Subodh ^l   Jian, Zhang ^l   Spinar, Jindrich ^l   Seronde, Marie France ^l   Böhm, Michael ^l   Merkely, Bela ^l   Chopra, Vijay ^l   Senni, Michele ^l   Taddei, Stefano ^l   Tsutsui, Hiroyuki ^l   Choi, Dong Ju ^l   Chuquiure, Eduardo ^l   La Rocca, Hans Pieter Brunner ^l   Ponikowski, Piotr ^l   Juanatey, Jose Ramon Gonzalez ^l   Squire, Iain ^l   Januzzi, James ^l,l   Pina, Ileana ^l   Pocock, Stuart J ^l   Carson, Peter ^l   Doehner, Wolfram ^l   Miller, Alan ^l   Haas, Markus ^l   Pehrson, Steen ^l   Komajda, Michel ^l   Anand, Inder ^l   Teerlink, John ^l   Rabinstein, Alejandro ^l   Steiner, Thorsten ^l   Kamel, Hooman ^l   Tsivgoulis, Georgios ^l   Lewis, James ^l   Freston, James ^l   Kaplowitz, Neil ^l   Mann, Johannes ^l   Petrie, Mark ^l   Bernstein, Richard ^l   Cheung, Alfred ^l   Green, Jennifer ^l   Kaul, Sanjay ^l   Ping, Carolyn Lam Su ^l   Lip, Gregory ^l   Marx, Nikolaus ^l   McCullough, Peter ^l   Mehta, Cyrus ^l   Rosenstock, Julio ^l   Sattar, Naveed ^l   Scirica, Benjamin ^l   Wanner, Christoph ^l   Welty, Francine K ^l   Parhofer, Klaus G ^l   Clayton, Tim ^l   Pedersen, Terje R ^l   Lees, Kennedy R ^l   Konstam, Marvin A ^l   Greenberg, Barry ^l   Palmer, Mike ^l   more..

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ATHENS   (Greece)

^e NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^g BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^h BOEHRINGER INGELHEIM CANADA LTD   (Canada)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k UNIVERSITÉ DE LORRAINE   (France)

^l Université de Lorraine ^*

more..

Author keywords

Diabetes; Heart failure; Reduced ejection fraction; SGLT2 inhibitors; Trial design

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EMPAGLIFLOZIN; ENKEPHALINASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HIGH RISK PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STUDY DESIGN; YOUNG ADULT; CHRONIC DISEASE; HEART FAILURE; HEART STROKE VOLUME; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BENZHYDRYL COMPOUNDS; CHRONIC DISEASE; GLUCOSIDES; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; STROKE VOLUME;

EID: 85069817778     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.1536     Document Type: Article

References (36)

1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128.
2. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–657.
3. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Ruff CT, Gause-Nilsson IA, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–357.
4. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenn BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295–2306.
5. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Trial Investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016;37:1526–1534.
6. Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, Woerle HJ, Hantel S, George JT, Johansen OE, Inzucchi SE; EMPA-REG OUTCOME Trial Investigators. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial. Eur Heart J 2018;39:363–370.
7. Rådholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation 2018;138:458–468.
8. Packer M. How have millions of people with heart failure benefited from our research over the last 10-15 years? The sounds of dead silence. Eur J Heart Fail 2017;19:1353–1354.
9. Packer M. Who should deliver medical therapy for patients with chronic heart failure? An immediate call for action to implement a community-based collaborative solution. Circ Heart Fail 2017;10:e004332.
10. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RH, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD; DECLARE–TIMI 58 Investigators. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 2019;139:2528–2536.
11. Hwang IK, Shih WJ, De Cani JS. Group sequential designs using a family of type I error probability spending functions. Stat Med 1990;9:1439–1445.
12. Yurista SR, Silljé HH, Oberdorf-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, van Goor H, van Veldhuisen DJ, de Boer RA, Westenbrink BD. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail 2019;21:862–873.
13. McMurray JJ, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD; DAPA-HF Committees and Investigators. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail 2019;21:665–675.
14. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587–597.
15. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323–334.
16. Hallow KM, Gebremichael Y, Helmlinger G, Vallon V. Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis. Am J Physiol Renal Physiol 2017;312:F819–F835.
17. Packer M, Claggett B, Lefkowitz MP, McMurray JJ, Rouleau JL, Solomon SD, Zile MR. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol 2018;6:547–554.
18. Hallow KM, Helmlinger G, Greasley PJ, McMurray JJ, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab 2018;20:479–487.
19. Neuberg GW, Miller AB, O'Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M; PRAISE Investigators. Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31–38.
20. Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CS, Lip GYH, Marx N, McCullough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Tsutsui H, Verma S, Wanner C, Woerle HJ, Zannad F, Anker SD; Trials Program EMPEROR. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail 2017;19:1390–1400.
21. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a "thrifty substrate" hypothesis. Diabetes Care 2016;39:1108–1114.
22. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 2016;39:1115–1122.
23. Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H, Dyck JE, Uddin GM, Oudit GY, Mayoux E, Lehrke M, Marx N, Lopaschuk GD. Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC Basic Transl Sci 2018;3:575–587.
24. 13C magnetic resonance spectroscopy study. Diabetes Obes Metab 2019;21:357–365.
25. Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, Flores E, Garcia-Ropero A, Sanz J, Hajjar RJ, Fuster V, Badimon JJ. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol 2019;73:1931–1944.
26. +-exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling. Br J Pharmacol 2008;154:1266–1275.
27. + exchanger in rats and rabbits. Diabetologia 2017;60:568–573.
28. + and vasodilation. Diabetologia 2018;61:722–726.
29. Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2017;2:1025–1029.
30. Packer M. Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation 2017;136:1548–1559.
31. Packer M. Reconceptualization of the molecular mechanism by which SGLT2 inhibitors reduce the risk of heart failure events. Circulation 2019, in press.
32. + exchanger activation. J Mol Cell Cardiol 2010;49:106–112.
33. Mustroph J, Wagemann O, Lücht CM, Trum M, Hammer KP, Sag CM, Lebek S, Tarnowski D, Reinders J, Perbellini F, Terracciano C, Schmid C, Schopka S, Hilker M, Zausig Y, Pabel S, Sossalla ST, Schweda F, Maier LS, Wagner S. Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail 2018;5:642–648.
34. Anker SD, Butler J. Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle. ESC Heart Fail 2018;5:549–551.
35. Byrne NJ, Parajuli N, Levasseur JL, Boisvenue J, Beker DL, Masson G, Fedak PW, Verma S, Dyck JR. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC Basic Transl Sci 2017;2:347–354.
36. Lee HC, Shiou YL, Jhuo SJ, Chang CY, Liu PL, Jhuang WJ, Dai ZK, Chen WY, Chen YF, Lee AS. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol 2019;18:45.